Acetic Acid

Acetic Acid

SCHEMBL482738

CC(=O)O.O=C1CCC(=O)N1O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35
GLA P06280 1/20 0.35
KMT2A Q03164 1/20 0.32
ATM Q13315 1/20 0.32
POLB P06746 1/20 0.32
ALDH1A1 P00352 1/20 0.31
PKM P14618 1/20 0.31
MAPT P10636 1/20 0.30
SLC1A2 P43004 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL21834859 1.00 FFAR3 (0.39) FFAR3LCKFYNCA12CA1
Bicarbonate SCHEMBL14917 0.88 CA1 (0.38) CA12CA1CA9POLBALDH1A1
Bicarbonate SCHEMBL6150295 0.88 CA1 (0.38) CA12CA1CA9POLBALDH1A1
SCHEMBL4147046 0.86 GLA (0.31) CA12CA1CA9GLA
SCHEMBL4147044 0.86 GLA (0.34) CA12CA1CA9GLAKMT2A
Methacrylic Acid SCHEMBL422938 0.85 KMT2A (0.39) CA12CA1CA9GLAKMT2A
SCHEMBL785147 0.85
Carbamic Acid SCHEMBL699756 0.83 ACHE (0.39) CA12CA1CA9ALDH1A1PKM
SCHEMBL6742810 0.83 CA12 (0.35) CA12CA1CA9POLBALDH1A1
Pivalate SCHEMBL10534446 0.82 POLB (0.34) CA12CA1CA9ATMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119280461-A In-situ cross-linked polypeptide gel and preparation method and application thereof 江苏德威兰医疗器械股份有限公司 2025-01-10 CN claimed
CN-114438047-B Method for preparing polyethylene glycol modified urate oxidase 重庆派金生物科技有限公司 2024-11-22 CN claimed
CN-114438048-B Urate oxidase preparation and application thereof 重庆派金生物科技有限公司 2024-10-22 CN claimed
CN-118497161-A Polyethylene glycol modified urate oxidase 重庆派金生物科技有限公司 2024-08-16 CN claimed
CN-118453890-A Composition for improving stability of polyethylene glycol asparaginase, pharmaceutical composition and application thereof 重庆派金生物科技有限公司 2024-08-09 CN claimed
CN-117866929-A Pegylated arginine deiminase dimer preparation and use thereof 重庆派金生物科技有限公司 2024-04-12 CN claimed
CN-116966279-A Covalently modified recombinant phenylalanine lyase enteric-coated preparation and application thereof 重庆派金生物科技有限公司 2023-10-31 CN claimed
CN-116106283-A Fluorescent analysis method and application of plasmalogens 清华大学 2023-05-12 CN claimed
CN-115869456-A Preparation of in-situ gelation anti-swelling enhanced tissue adhesive material 上海其胜生物制剂有限公司 2023-03-31 CN claimed
WO-2022095974-A1 METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE 杭州远大生物制药有限公司 2022-05-12 WO claimed
CN-111909906-A Urate oxidase modified by polyethylene glycol 重庆派金生物科技有限公司 2020-11-10 CN claimed
CN-111868253-A Method for extracting nucleic acid 生物梅里埃公司 2020-10-30 CN claimed
CN-104628006-B A kind of preparation method of half strawberry type Janus particle 天津工业大学 2019-10-18 CN claimed
US-10266819-B2 Robust, easy to use immobilized enzyme reactors PERFINITY BIOSCIENCES, INC. (US) 2019-04-23 US claimed
EP-2344200-A2 MODIFIED THERAPEUTICS PEPTIDES, METHODS OF THEIR PREPARATION AND USE Nektar Therapeutics (US) 2011-07-20 EP claimed
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2011-07-14 US claimed
WO-2010033220-A2 MODIFIED THERAPEUTICS PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2010-03-25 WO claimed
EP-1370295-A2 NEUTRAL AND ANIONIC COLLOIDAL PARTICLES FOR GENE DELIVERY GENCELL S.A. (FR) 2003-12-17 EP claimed
US-20020146829-A1 Neutral and anionic colloidal particles for gene delivery AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-10-10 US claimed
WO-2002043769-A2 NEUTRAL AND ANIONIC COLLOIDAL PARTICLES FOR GENE DELIVERY GENCELL S.A. (FR) 2002-06-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE DNPEP, VIP, PTMS FFAR3 3053/4885LCK 1709/4885FYN 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.